Clinical Trial Search

Primary: Responder Rate Compared to the Untreated Control Group According to the Merz Infraorbital Hollow Assessment Scale (MIHAS). — 81.6; 9.5 percentage of participants — p=<…

Primary: Responder Rate Based on the Blinded Evaluator's Live Assessment of the Galderma Infraorbital Hollows Scale (GIHS) — 87.4; 17.7 Percentage of participants — p=<0.001

Primary: Volumetric Change in Infraorbital Treatment Baseline to Each Post-intervention Timepoint Day 14, Day 30, and Day 90 — -0.026; -0.065; -0.108 cc

Primary: Percentage of Participants With at Least a 1-point Improvement Change From Baseline on the Allergan Infraorbital Hollows Scale (AIHS) Based on Evaluating Investigator's…

Primary: Percentage of Subjects With a ≥1 Grade Improvement From Baseline in Infra-Orbital Area on the Allergan Infra-Orbital Rating Scale (AIRS) on the Right and Left Side — 99…

Primary: The Primary Objective of This Study is to Determine the Efficacy and Longevity of the Use of Restylane® and Perlane® in Combination for the Rejuvenation of the…

Primary: Responder Rate Based on Merz Infraorbital Hollow Assessment Scale (MIHAS) at Week 8 — 80.6; 87.4; 73.7; 1.9 percentage of subjects

Primary: Change of 1 Point From Baseline in Infra-Orbital Hollows Severity Rated by the Blinded Live Evaluator (BLE) at Week 12 After Last Treatment, Using the TIOHS - Phase 1a…

Primary: Number of Participants With Adverse Events — 23; 59; 1; 2 Participants

Primary: Responder Rate Based on the Blinded Evaluators' Live Assessment of the Galderma Temple Volume Deficit Scale (GTVDS) — 91.2; 9.1 percentage of participants — p=<0.001

Primary: Percentage of Participants With ≥ 1-grade Improvement From Baseline in the Validated Allergan Temple Hollowing Scale (ATHS) Based on Evaluating Investigator (EI)…

Primary: Graded Change in Dermatochalasis — .2679 units on a scale

Primary: Nasal Tip Projection — 0.601 ratio

Primary: Blinded Evaluations of First Impression — 7.35 score on a scale

Primary: Blinded Physician Jawline Rating Scale (JRS) Assessment on Scale of 0 to 4 at Baseline Versus 4 Weeks After Last Injection. — 2.214; 2.071; 1.857; 1.857 score on a scale…

Primary: Responder Rate in Reduction of Nasolabial Folds — 34; 39; 73 Participants

Primary: Number of Participants Who Showed Improvement in Under Eye Swelling and Dark Circles Relative to Baseline Per Intervention — 0; 0 participants — p==1

Primary: Change in Lower Eyelid Bags. — 5; 5 Participants

Primary: Percentage of Participants With 1 Point Improvement From Baseline on the Medicis Midface Volume Scale (MMVS) as Measured by the Blinded Evaluator at Month 12 — 68.8…

Primary: First Impressions — 46.756; 27.769; 46.391; 34.404 score on a scale

Primary: Percentage of Participants (Responders) With At Least 1-Point Improvement From Baseline on the GCRS, as Assessed by the Blinded Evaluator at Month 6 ([Baseline…

Primary: Percent Responders With 1 Point Improvement on the Medicis Midface Volume Scale — 67; 8 Participants

Primary: Lateral Wall Thickness — 161 mm

Primary: Mean Change From Baseline in Wrinkle Severity Rating Scale (WSRS) at 6 Months — -0.03; 0.03 units on a scale

Primary: NLF-SRS Grade of Nasolabial Folds Change — -1.50 score on a scale

Primary: Responder Status Based on Independent Evaluating Investigator Live Assessment at Week 24 - Full Analysis Dataset — 222; 221 Participants — p=<0.0001

Primary: Day 180 Number of Participants With Improvement in Lower Eyelid Area as Determined by a Masked, Qualitative Assessment. — 5 Participants

Primary: Lid-Parallel Conjunctival Folds (LIPCOF) — 1.95; 1.75; 1.70; 1.40 Score

Primary: Assess Efficacy of Study Treatment Using Medicis Midface Volume Score (MMVS) — -1.4; -0.1; -1.3 score on a scale

Primary: Percentage of Responders — 80; 87.2; 76.7 percentage of subjects